Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $154,777 | 2 | 75.7% |
| Consulting Fee | $44,002 | 14 | 21.5% |
| Travel and Lodging | $4,782 | 7 | 2.3% |
| Food and Beverage | $918.49 | 23 | 0.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $154,777 | 2 | $0 (2021) |
| ABBVIE INC. | $14,192 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $10,558 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $8,063 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,808 | 10 | $0 (2023) |
| Janssen Biotech, Inc. | $5,945 | 8 | $0 (2019) |
| Sobi, Inc | $3,000 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $110.88 | 1 | $0 (2024) |
| Amgen Inc. | $24.86 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,392 | 17 | ABBVIE INC. ($14,192) |
| 2023 | $1,039 | 3 | GlaxoSmithKline, LLC. ($975.00) |
| 2022 | $12,175 | 11 | AstraZeneca Pharmaceuticals LP ($7,744) |
| 2021 | $162,918 | 6 | Eli Lilly and Company ($154,766) |
| 2020 | $11.00 | 1 | Eli Lilly and Company ($11.00) |
| 2019 | $5,945 | 8 | Janssen Biotech, Inc. ($5,945) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/17/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $110.88 | General |
| 11/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $7,735.00 | General |
| 11/11/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.66 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.27 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.55 | General |
| 06/21/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $13,975.00 | General |
| 05/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $22.11 | General |
| 05/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $17.39 | General |
| 05/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $8.23 | General |
| 05/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $7.62 | General |
| 05/01/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $106.92 | General |
| 05/01/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $22.11 | General |
| 05/01/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $16.42 | General |
| 05/01/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $9.06 | General |
| 05/01/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $7.62 | General |
| 12/13/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $31.28 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/26/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $32.84 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/04/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $3,759.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/12/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $54.74 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/09/2022 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/19/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $2,685.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/19/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $270.97 | General |
| Category: Inflammation and Autoimmunity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 INFECTION | Eli Lilly and Company | $154,777 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 103 | 115 | $54,721 | $10,170 |
| 2022 | 1 | 59 | 62 | $17,170 | $4,463 |
| 2021 | 3 | 105 | 142 | $34,220 | $13,375 |
| 2020 | 8 | 213 | 259 | $57,115 | $23,477 |
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 70 | $27,366 | $4,922 | 18.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $13,680 | $2,901 | 21.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $13,675 | $2,347 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 30 | $10,770 | $2,417 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 29 | 32 | $6,400 | $2,046 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 83 | $16,600 | $6,662 | 40.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 24 | 32 | $8,320 | $3,546 | 42.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 27 | 27 | $9,300 | $3,168 | 34.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 26 | $10,420 | $4,578 | 43.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 38 | 48 | $9,600 | $4,040 | 42.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 33 | 33 | $10,035 | $3,946 | 39.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 20 | $5,200 | $2,338 | 45.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 31 | $4,380 | $1,946 | 44.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 24 | 27 | $3,510 | $1,624 | 46.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 19 | 22 | $4,400 | $1,431 | 32.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 14 | $3,785 | $1,360 | 35.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $3,420 | $1,294 | 37.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 20 | 27 | $2,365 | $920.61 | 38.9% |
About Dr. Roberto Caricchio, M.D
Dr. Roberto Caricchio, M.D is a Rheumatology healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2008. The National Provider Identifier (NPI) number assigned to this provider is 1376708032.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roberto Caricchio, M.D has received a total of $204,480 in payments from pharmaceutical and medical device companies, with $22,392 received in 2024. These payments were reported across 46 transactions from 9 companies. The most common payment nature is "" ($154,777).
As a Medicare-enrolled provider, Caricchio has provided services to 480 Medicare beneficiaries, totaling 578 services with total Medicare billing of $51,486. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Practice Information
- Specialty Rheumatology
- Location Worcester, MA
- Active Since 07/22/2008
- Last Updated 06/03/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1376708032
Products in Payments
- SAPHNELO (Biological) $7,808
- BENLYSTA (Biological) $7,247
- SIMPONI ARIA (Biological) $5,945
- KINERET (Drug) $3,000
- Blincyto (Biological) $24.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Worcester
Timothy Mcalindon, Md, Mph, MD, MPH
Rheumatology — Payments: $208,974
Elinor Mody, Md, MD
Rheumatology — Payments: $18,340
Dr. Jonathan Cheah, Md, MD
Rheumatology — Payments: $7,087
Eric Jacobson, M.d, M.D
Rheumatology — Payments: $5,708
Raymond Pertusi, Do, DO
Rheumatology — Payments: $749.91
Elena Gkrouzman, Md, MD
Rheumatology — Payments: $190.65